Categories
Tags
Authors: Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W DOI: 10.1056/NEJMoa2118542 Abstract BACKGROUND Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in vitro. METHODS We conducted a phase 2–3 double-blind, randomized, controlled trial in which symptomatic, [...]
Categories: I-CARE Early Covid
Tags: COVID-19, nirmatrelvir
Authors: Lee TC, Vigod S, Hanula R, Boulware DR, Lenze EJ PMID: 35385087 PMCID: PMC8987902 DOI: 10.1001/jamanetworkopen.2022.6269 Abstract Importance: Widely available and affordable options for the outpatient management of COVID-19 are needed, particularly for therapies that prevent hospitalization. Objective: To perform a meta-analysis of the available randomized clinical trial evidence for fluvoxamine in the outpatient [...]
Categories: I-CARE Early Covid
Tags:
Authors: Olas B PMID: 35405963 PMCID: PMC9002813 DOI: 10.3390/nu14071350 Abstract Cardiovascular diseases (CVDs) have been the leading cause of death for over 20 years. The main causative factors are believed to be high cholesterol, obesity, smoking, diabetes, and a lack of physical activity. One of the most commonly used treatments is a combination of anticoagulant [...]
Categories: I-CARE Early Covid, I-CARE Flu and RSV, I-RECOVER Post-Vaccine
Tags: cardiovascular, dandelion
Authors: Puskarich MA, Ingraham NE, Merck LH, Driver BE, Wacker DA, Black LP PMID: 35294537 PMCID: PMC8928006 DOI: 10.1001/jamanetworkopen.2022.2735 Abstract Importance: SARS-CoV-2 viral entry may disrupt angiotensin II (AII) homeostasis, contributing to COVID-19 induced lung injury. AII type 1 receptor blockade mitigates lung injury in preclinical models, although data in humans with COVID-19 remain mixed. [...]
Categories: I-CARE Early Covid
Authors: Hazan S, Dave S, Gunaratne AW, Dolai S, Clancy RL, McCullough PA et al. PMID: 35135310 PMCID: PMC8826831 DOI: 10.2217/fmb-2022-0014 Abstract Aims: Ivermectin is a safe, inexpensive and effective early COVID-19 treatment validated in 20+ random, controlled trials. Having developed combination therapies for Helicobacter pylori, the authors present a highly effective COVID-19 therapeutic [...]
Categories: I-CARE Early Covid, MATH+
Tags: COVID-19, ivermectin
Authors: Willett BJ, Grove J, MacLean OA, Willkie C, Logan N doi: https://doi.org/10.1101/2022.01.03.21268111 Abstract Vaccines based on the spike protein of SARS-CoV-2 are a cornerstone of the public health response to COVID-19. The emergence of hypermutated, increasingly transmissible variants of concern (VOCs) threaten this strategy. Omicron, the fifth VOC to be described, harbours 30 amino [...]
Categories: I-CARE Early Covid
Tags:
Authors: Izquierdo JL, Soriano JB, Gonzalez Y, Lumbreras S PMID: 35084258 PMCID: PMC8795755 DOI: 10.1177/00368504221074574 Abstract Infection by SARS-CoV-2 causing coronavirus disease 2019 (COVID-19) can be associated with serious and life-threatening conditions, including acute respiratory distress syndrome (ARDS). Severity and mortality have been related to a cytokine storm, an imbalance of oxidative stress, and a [...]
Categories: I-CARE Early Covid, I-RECOVER Long Covid, I-RECOVER Post-Vaccine, MATH+
Tags: COVID-19, N-Acetylcysteine
Authors: Rondanelli M, Perna S, Gasparri C, Petrangolini G, Cavioni A, Peroni G. PMID: 35054459 PMCID: PMC8780248 DOI: 10.3390/life12010066 Abstract Quercetin, for its crucial properties, fulfills the need for a multifactor action that is useful for the potential counterbalance of a COVID-19 infection. Given this background, the aim of the study was to evaluate the [...]
Categories: I-CARE Early Covid, I-PREVENT, I-RECOVER Post-Vaccine
Tags: quercetin
Authors: Clemency BM, Varughese R, Morse CG, Koster DJ, Blaiss MS PMID: 34807241 PMCID: PMC8609464 DOI: 10.1001/jamainternmed.2021.6759 Abstract Importance: Systemic corticosteroids are commonly used in treating severe COVID-19. However, the role of inhaled corticosteroids in the treatment of patients with mild to moderate disease is less clear. Objective: To determine the efficacy of the inhaled [...]
Categories: I-CARE Early Covid
Tags: ciclesonide, COVID-19
Authors: Kumar P, Osahon O, Vides DB, Hanania N, Minard CG PMID: 35052554 PMCID: PMC8773164 DOI: 10.3390/antiox11010050 Abstract Humanity is battling a respiratory pandemic pneumonia named COVID-19 which has resulted in millions of hospitalizations and deaths. COVID-19 exacerbations occur in waves that continually challenge healthcare systems globally. Therefore, there is an urgent need to understand [...]
Categories: I-CARE Early Covid, MATH+
Tags: COVID-19, Glutathione